Search
Bentiromide
go.drugbank.com/drugs/DB00522ApprovedWithdrawnBentiromide is currently not available in the U.S. or Canada.
Delamanid
go.drugbank.com/drugs/DB11637ApprovedInvestigationalDelamanid is approved by the EMA and is marketed under the trade name Deltyba as oral tablets. It is marketed by Otsuka Pharmaceutical Co., Ltd (Tokyo, Japan). … Spontaneous resistance to delamanid was observed during treatment, where mutation in one of the 5 F420 coenzymes responsible for bioactivation of delamanid contributes to this effect [L1407].
Technetium Tc-99m pertechnetate
go.drugbank.com/drugs/DB09314ApprovedInvestigationalFollowing intravenous injection, single photon emission computed tomography (SPECT) is performed to detect the gamma ray emmitted by the decay of Technetium-99m to Technetium-99. … However, in contrast to the iodide ion, the pertechnetate ion is released unchanged from the thyroid gland.
Products: MON.TEK 99 MO/99MTC JENERATÖR, 10 GBQ, MON.TEK 99 MO/99MTC JENERATÖR, 15 GBQDorocubicel
go.drugbank.com/drugs/DB19448Approvedmarketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation following myeloablative conditioning in adult patients for whom a suitable donor is not
Avanafil
go.drugbank.com/drugs/DB06237ApprovedIn comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively … [L32113] It first received FDA approval on April 27, 2012,[L32058] with subsequent EMA approval in June 2013.[L32113]
Synonyms: (S)-4-(3-Chloro-4-methoxybenzylamino)-2-(2-hydroxymethylpyrrolidin-1-yl)-N-pyrimidin-2-ylmethyl-5-pyrimidinecarboxamideElamipretide
go.drugbank.com/drugs/DB11981ApprovedInvestigational[A274436] Elamipretide is a synthetic tetrapeptide that selectively binds to cardiolipin, a phospholipid in the inner mitochondrial membrane. … Food and Drug Administration (FDA) granted accelerated approval for FORZINITY™ (elamipretide) to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg.
Trospium
go.drugbank.com/drugs/DB00209ApprovedInvestigational[L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.[L6211] … [L6208] An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination.
Lifileucel
go.drugbank.com/drugs/DB17107ApprovedInvestigationalthe FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma. … immunotherapy composed of a suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and activation[A263341] Lifileucel was granted accelerated approval by
Inebilizumab
go.drugbank.com/drugs/DB12530ApprovedInvestigationalInappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis … Compared to the anti-CD20 antibody [rituximab], which is also used to treat NMOSD, inebilizumab has broader specificity.
Delavirdine
go.drugbank.com/drugs/DB00705ApprovedInvestigationalWithdrawnA potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Synonyms: (N-[2-[4-[3-(1-methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide), 2-(4-(5-methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamineCategories: Non-Nucleoside Reverse Transcriptase Inhibitors, Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor